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DOI 10.1186/s12879-015-0859-2RESEARCH ARTICLE Open AccessCost effectiveness of option B plus for prevention
of mother-to-child transmission of HIV in
resource-limited countries: evidence from
Kumasi, Ghana
Adam VanDeusen1, Elijah Paintsil2*, Thomas Agyarko-Poku3 and Elisa F Long4Abstract
Background: Achieving the goal of eliminating mother-to-child HIV transmission (MTCT) necessitates increased
access to antiretroviral therapy (ART) for HIV-infected pregnant women. Option B provides ART through pregnancy
and breastfeeding, whereas Option B+ recommends continuous ART regardless of CD4 count, thus potentially
reducing MTCT during future pregnancies. Our objective was to compare maternal and pediatric health outcomes
and cost-effectiveness of Option B+ versus Option B in Ghana.
Methods: A decision-analytic model was developed to simulate HIV progression in mothers and transmission (in
utero, during birth, or through breastfeeding) to current and all future children. Clinical parameters, including
antenatal care access and fertility rates, were estimated from a retrospective review of 817 medical records at two
hospitals in Ghana. Additional parameters were obtained from published literature. Modeled outcomes include HIV
infections averted among newborn children, quality-adjusted life-years (QALYs), and cost-effectiveness ratios.
Results: HIV-infected women in Ghana have a lifetime average of 2.3 children (SD 1.3). Projected maternal life
expectancy under Option B+ is 16.1 years, versus 16.0 years with Option B, yielding a gain of 0.1 maternal QALYs
and 3.2 additional QALYs per child. Despite higher initial ART costs, Option B+ costs $785/QALY gained, a value
considered very cost-effective by World Health Organization benchmarks. Widespread implementation of Option B+
in Ghana could theoretically prevent up to 668 HIV infections among children annually. Cost-effectiveness estimates
remained favorable over robust sensitivity analyses.
Conclusions: Although more expensive than Option B, Option B+ substantially reduces MTCT in future
pregnancies, increases both maternal and pediatric QALYs, and is a cost-effective use of limited resources in Ghana.
Keywords: HIV prevention, Mother-to-child HIV transmission, Cost-effectiveness analysis, Mathematical modelBackground
Global efforts to reduce mother-to-child transmission
(MTCT) of HIV have made substantial progress with a
52% reduction in new infections occurring in children
between 2001 and 2012, in large part due to improved
access to antiretroviral therapy (ART) among pregnant
women [1]. Despite this considerable progress, only 67%
of pregnant women living with HIV in low- and middle-* Correspondence: Elijah.paintsil@yale.edu
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unless otherwise stated.income countries received ART in 2013 (http://www.who.
int/mediacentre/factsheets/fs360/en). The prevention of
MTCT (PMTCT) of HIV in resource-limited countries is
hindered by factors such as breastfeeding practices, inad-
equate healthcare infrastructure, potential stigma associ-
ated with not breastfeeding, and competing public health
priorities in the face of limited healthcare resources. In
June 2011, the United Nations General Assembly High
Level Meeting on AIDS affirmed the Global Plan towards
the elimination of new HIV infections among children by
2015 and keeping their mothers alive [2].tral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
VanDeusen et al. BMC Infectious Diseases  (2015) 15:130 Page 2 of 10The World Health Organization (WHO) currently rec-
ommends two strategies to eliminate MTCT: Option B
and Option B+. Option B, the current recommendation
in Ghana, consists of antiretroviral prophylaxis that be-
gins early in gestation and continues through breastfeed-
ing for women with a CD4 count above 350 cells/mm3,
and lifetime ART for women with a CD4 count below
350 cells/mm3 [3]. Option B guidelines have the poten-
tial to reduce rates of MTCT to as low as 1%, assuming
high access to antenatal services [4]. Additionally, Op-
tion B can improve maternal health and is preferred to
the previously recommended option of single-dose nevi-
rapine during delivery, despite the higher cost of Option
B [4]. Option B+ proposes that all HIV-infected preg-
nant women receive lifelong ART beginning at their first
pregnancy, regardless of CD4 cell count [2]. This strat-
egy may improve maternal health through reduced mor-
bidity and mortality, and reduce overall MTCT,
especially in settings with high fertility rates [2]. How-
ever, the cost implications of implementing Option B+
in resource-limited settings such as Ghana are uncertain
and have not been thoroughly studied.
According to the Ghana AIDS Commission Sentinel
Survey for 2013, an estimated 224,488 people were living
with HIV/AIDS in Ghana, including 34,557 children
(15% of total) [5]. Although the epidemic has stabilized
with a seroprevalence of 1.3% in the general population
and 1.9% among pregnant women, an estimated 2,407
new pediatric infections occurred in 2013, which ac-
counts for 30% of all new infections [6]. Antiretroviral
therapy was introduced to Ghana in 2003 and the pro-
gram has been widely scaled up; as of the end of Decem-
ber 2012, there were a total of 165 ART sites in the
country [7]. In 2001, the Ministry of Health of Ghana
initiated a broad PMTCT program using single-dose ne-
virapine, and Option B was adopted in 2011, with 1,656Table 1 Costs considered in estimates of HIV-related care
Direct costs Indirect costs – facility level
Staff time caring for clients Administrative staff time
Drugs to prevent & treat
opportunistic infections
Supervision from regional level
ARV drugs Office equipment
Medical consumables & supplies
in clinic visits
Vehicles used for program
administration
Laboratory testing Transportation costs for
administration
Medical equipment Public utilities
Physical infrastructure used for
client care
Maintenance & repair
Staff training
Legal & auditing costsPMTCT sites established by December 2012. With more
than 90% of pregnant women having access to antenatal
care in Ghana, eliminating MTCT in the near future is
within reach [5].
A key consideration when evaluating the benefits of
continuous ART versus interrupted therapy is the time be-
tween successive pregnancies. Because Option B results in
the cessation of ART following breastfeeding completion,
a woman may not receive ART at the optimal starting
point (i.e., before the end of the first trimester) of her next
pregnancy. With Option B+, she remains continuously on
ART, so there is no window during a future pregnancy
when she is not receiving prophylactic therapy, assuming
adherence to therapy.
In this study, we aim to evaluate the potential health
benefits – to the mother and all future children – and
cost-effectiveness of Option B+ versus Option B in
Ghana, to help inform HIV therapy recommendations
for pregnant women in resource-limited countries. In
addition, we summarize primary data collected from two
hospitals in Ghana, including the timing and number of
pregnancies occurring over a woman’s lifetime. Prior
studies have evaluated Option B+ in other settings, but
to the best of our knowledge, no prior study has in-
cluded multiple pregnancies in the economic evaluation
of Option B+, which is needed to fully capture the im-
pact of continuous therapy regimens in settings where
many women have multiple children [8-11].
Methods
We developed a state-transition model to compare the
costs and benefits of two strategies (Option B versus
Option B+) to prevent MTCT in Ghana. Transmission
rates, life expectancies, and ART adherence rates were
obtained from the Ghana Health Service [7,12]. Table 1
illustrates variables used in estimating HIV-related costIndirect costs – program
support
Costs not included in analysis
Support from national ART
program
Client time, transport, meals,
and other client costs
Support from Ghana Health
Service
Costs incurred by local communities
Negative externalities
Technical assistance or administrative
costs incurred by external donor agencies
VanDeusen et al. BMC Infectious Diseases  (2015) 15:130 Page 3 of 10of care. Estimates for costs, utilities, disease progression
rates, testing patterns by CD4 count, and development
of ART resistance were obtained from published studies
[7,13-20].
Patient characteristics
The population under consideration is HIV-infected
pregnant women in Ghana, who are pregnant with their
first child. Data collection consisted of abstracting infor-
mation about patient characteristics from paper medical
charts at two government hospitals in Kumasi, Ghana
(Table 2). These hospitals serve a range of women from
Kumasi and its surrounding region, and their patients
were considered representative of the overall population.
All complete charts of HIV+ women receiving care at
the two centers from January 2008 to June 2012 were
reviewed. Based on the medical chart review, we obtained
estimates of antenatal care access patterns, average base-
line CD4 count at initiation of antenatal care, age of first
pregnancy, lifetime number of children per woman, and
time between successive pregnancies (Table 2). Maternal
life expectancy was evaluated using medical charts and
death records at each hospital. The study protocol wasTable 2 Characteristics of study population
Parameter Count (% of total) or
mean (±SD)*
Charts Reviewed 817
Suntreso Government Hospital 418 (51.2%)
Kumasi South Hospital 399 (48.8%)
Age of first pregnancy 22.78 years (±4.97 years)
Pregnant when diagnosed
HIV-positive
223 (27.3%)
Baseline CD4 count 471 cells/mm3
(±299 cells/mm3)
CD4 < 350 cells/mm3 when
pregnant and diagnosed
118 (52.9%)
Month of pregnancy when
first accessing care (n = 92)
1st trimester 11 (12.0%)
Month 1 1 (1.1%)
Month 2 4 (4.4%)
Month 3 6 (6.5%)
2nd trimester 37 (40.2%)
Month 4 11 (12.0%)
Month 5 14 (15.2%)
Month 6 12 (13.0%)
3rd trimester 44 (47.8%)
Month 7 19 (20.7%)
Month 8 19 (20.7%)
Month 9 6 (6.5%)
*Percentages may not add to 100% due to rounding.reviewed and approved by Institutional Review Boards at
Yale School of Medicine and Kwame Nkrumah University
of Science and Technology. No informed consent was ob-
tained since patient information was anonymized and de-
identified prior to analysis.Definition of options
Option B and Option B+ are the two most comprehen-
sive options recommended for the prevention of MTCT
by the WHO [21]. Under both options, an HIV+ preg-
nant woman with CD4 count <350 cells/mm3 is immedi-
ately treated with triple-ART that continues through life.
Option B provides that women with CD4 > 350 cells/
mm3 receive ART beginning at 14 weeks into gestation,
throughout pregnancy, and after birth until breastfeed-
ing ceases. Under Option B+, all women receive lifetime
ART, even if CD4 count is >350 cells/mm3. Under both
options, infants born to HIV+ women receive daily zi-
dovudine (AZT) for the first 4–6 weeks of life [22].Model structure
We developed a state-transition model to calculate the
average lifetime costs and health benefits associated with
Option B+ or Option B (Figure 1). The model consists
of several health states in which an HIV+ woman can
exist, and transition probabilities that relate to the likeli-
hood of moving to a different health state in the next
time period. A woman remains in each state for a time
unit of three months (a “cycle”), with the exception of
the “Dead” state, in which a woman remains in this ab-
sorbing state.
To ensure appropriate lengths of pregnancy and
breastfeeding, women are restricted to remain in the
pregnancy state for nine months (3 cycles) and remain
in either of the breastfeeding states for six months (2 cy-
cles). The model initially assigns to each mother a start-
ing age, CD4 cell count, and month of pregnancy, based
on data obtained from chart review (Table 2). The model
then tracks the mother’s CD4 count, pregnancy and
antenatal care status, as well as the HIV status of her
child following birth. Transitions between health states
differed between treatment regimens, due to clinical dif-
ferences in CD4 count decline and mortality. Unlike
Markov models, which assume that all states are “mem-
oryless” or ignore past states, our model allows for future
transitions to depend on past events, such as number of
previous pregnancies. By relaxing this Markov assump-
tion, we can create a more clinically realistic model,
whereby a woman’s past health states can impact her fu-
ture states. Sensitivity analyses were conducted on all vari-
ables with ranges given in Table 3. The model was
implemented in TreeAge Pro 2012. Additional file 1
model details are provided in the Technical Appendix.
Figure 1 State transition model overview. A schematic diagram for the state transition model is given. Each oval represents a health state in
which a woman can exist. She remains in a state for the period of time indicated underneath each oval. Each arrow represents a transition to the
next state, which occurs with the probability indicated below each arrow.
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Fertility rates
Based on medical chart review, a probability hazard
function was fit to estimate the rate of future pregnan-
cies following the first pregnancy (Figure 2). Each preg-
nancy recorded from the chart review was considered an
event and the age at which these events occurred was in-
cluded in the model. This hazard model then produced
the probability of a subsequent pregnancy occurring at
each age in a woman’s lifetime. The model was devel-
oped in SAS 9.3.Access to antenatal care
In Ghana a pregnant woman initiates antenatal care at a
health facility during the first trimester of pregnancy; there
are at least four antenatal care visits for an uncomplicated
pregnancy [21]. The routine services provided at antenatal
visits include assessing for pregnancy complications (e.g.,
anemia, hypertension, and bleeding), nutritional advice,
immunization, HIV testing and counselling, monitoring of
pregnancy progress, and assessment of maternal and fetal
well-being. For HIV-infected pregnant women, monitor-
ing of ART side effects and compliance to treatment are
assessed at each visit. The overall fraction of pregnant
women in Ghana who receive antenatal care at some
point in their pregnancy was determined from a national
survey [7]. We determined the proportions of pregnant
women accessing antenatal care, by month of pregnancy,
from medical chart review.ART initiation and adherence
Estimates of ART adherence and the probability of
mother-to-child transmission during pregnancy, delivery,
or while breastfeeding were obtained from annual re-
ports issued by the Ghana Health Service (Table 3)
[7,12]. Under Option B, a woman who does not qualify
for lifetime therapy at her first pregnancy (by having a
CD4 cell count >350 cells/mm3) can initiate ART once
when her CD4 cell count decreases below 350 cells/
mm3. Women who qualify are provided ART at the first
possible event – either pregnancy or CD4 below the 350
cells/mm3 threshold [8]. Our model tracks CD4 cell
count throughout a woman’s lifetime and accounts for
ART initiation once this threshold is reached.
Mother-to-child transmission
Estimates of transmission rates dropping to 1% among
women receiving Option B assume ideal conditions (i.e.,
a pregnant woman receives therapy from the beginning
of her first trimester through six months of breastfeed-
ing) [12]. However, these rates are not achievable if ante-
natal care is initiated beyond the first trimester of
pregnancy. To estimate a more realistic transmission
rate for Option B, we multiplied the percentage of
women accessing antenatal care during each month of
pregnancy by a scaled transmission rate. This scaled
MTCT rate increased from 1.0% if a woman accessed
antenatal care during the first three months of preg-
nancy, up to 20.3% if antenatal care began in the ninth
month, generating an overall transmission rate during
Table 3 Model parameters
Variable Value Range Source
Demographic variables
Annual maternal mortality rates UNICEF [20]
<12 months ART
>350 cells/mm3 3.3% -
200-350 cells/mm3 3.9% -
<200 cells/mm3 11.1% -
>12 months ART
>350 cells/mm3 1.0% -
200-350 cells/mm3 1.1% -
<200 cells/mm3 1.8% -
Number of children 2.34 1-5 Chart review
Transition Probabilities
Access to care 82% 50-95% Ghana Health Service [7]
Adherence to ART 90% 50-95% Ghana Health Service [7]
Transmission during pregnancy
No therapy/non-adherence 22% 15-30% Ghana Health Service [12]
Option B 10%Ϯ 0-15% Ghana Health Service [12]
Option B-Plus 1% 0-5% Ghana Health Service [12]
Transmission during breastfeeding
No therapy/non-adherence 10% 5-20% Ghana Health Service [12]
Option B 1% 0-5% Ghana Health Service [12]
Option B+ 1% 0-5% Ghana Health Service [12]
Changes to CD4 Count
No therapy (every 3 months) −12.75 cells/mm3 5-20 cells/mm3 Holmes 2006 [15]
Initiate therapy +153 cells/mm3 100-400 cells/mm3 Deeks 1999 [16]
Continue therapy (every 3 months)
Previously interrupted therapy −0.06365 × [Current CD4] - Ickovics et al. 2001 [14]
Continuous therapy - 0.0099853 × [Current CD4] - Ickovics et al. 2001 [14]
Costs in USD [GHS]
Annual Cost of HIV Care
First-Line ART 385.45 [743.91] 191-580 WHO 2011 [17]; Rosen, J., and F. Asante. 2010 [18]
Second-Line ART 848.33 [1,637.28] - WHO 2011 [17]; Rosen, J., and F. Asante. 2010 [18]
Lifetime Cost of Care for HIV+ Child
(including ART costs)
10,665.49 [20,584.40] 5,181-15,544 WHO 2011 [17]; Rosen, J., and F. Asante. 2010 [18]
Quality-of-life Factor
HIV+ adult (quality of life) 0.8 0.50-1.0 Tengs T.O., Lin T.H. 2002 [19]
HIV+ child (lifetime QALYs) 20.2ϮϮ 10-30 UN Impact of AIDS 2004 [32]
HIV- child (lifetime QALYs) 62.7 50-70 UN Impact of AIDS 2004 [32]
Discount rate 0.03 0.00-0.05 Weinstein et al. 1996 [23]
ϮProbability of transmission during pregnancy/delivery while on Option B was determined by applying the distribution of when women accessed antenatal care
(found through chart review) with ideal conditions of Option B (beginning therapy at the beginning of the second trimester) indicated by the Ghana Health
Service and WHO.
ϮϮLifetime QALYs for an HIV-positive child assume a life expectancy at birth of 47.1 years [32] with a yearly utility of 0.82 and a discount rate of 0.03.
VanDeusen et al. BMC Infectious Diseases  (2015) 15:130 Page 5 of 10pregnancy/delivery of 10.2% for all pregnancies under
Option B. Under Option B+, this rate applied for only
the first pregnancy; subsequent pregnancies assumed atransmission rate of 1.0%. Further details can be found
in Additional file 1: Table S2 of the Technical Appen-
dix. Transmission rates were examined under robust
Figure 2 Probability distribution of time between 1st and 2nd pregnancy. The fraction of women (n = 817) who wait a given number of
years between their first and second pregnancy is shown, with the number of years indicated on the x-axis and the proportion of women
indicated on the y-axis. “0 years” indicates that the mother had only one child.
VanDeusen et al. BMC Infectious Diseases  (2015) 15:130 Page 6 of 10sensitivity analyses in case adherence rates increase or
decrease.
Additional model parameters
Additional values not available through chart review
were acquired from previously published studies. All
costs are reported in US Dollars (1 USD = 1.93 Ghana
Cedi, abbreviated as GHS) and incorporate all compo-
nents of HIV/AIDS care following diagnosis, including
ART, medical personnel wages, and CD4 count and viral
load testing. In particular, we assumed that the annual
cost of HIV/AIDS care with first-line ART is $385 or
744 GHS (3-month cost of $96 or 186 GHS), but we
consider variations of this assumption in sensitivity ana-
lysis (Table 3) [17,18].
Changes in CD4 cell count were modeled from previ-
ously published works and the rate of CD4 change was
determined by a woman’s ART utilization and whether
ART is interrupted or continuous [14,15]. Women in-
curred a CD4 cell count increase of 153 cells/mm3 at
the initiation of therapy [16].
Adjustments for quality-of-life while living with HIV
were considered as a yearly adjustment for adults and a
lifetime adjustment for children. Adult women living with
HIV were assumed to have 0.8 times the quality-of-life of
otherwise healthy women [19]. Children born HIV+ were
attributed this same 0.8 quality-of-life adjustment, applied
across life expectancy and discounted at an annual rate of
3% [23].
Mortality rates were obtained from a Business Leader-
ship Council/UNICEF report and considered a woman’s
CD4 count, as well as the length of time she has been
receiving therapy [20].Model outcomes
Primary outcomes of the model were costs and quality-
adjusted life years (QALYs) for each therapy option. All
costs and QALYs were discounted to the present using a
3% annual rate [23]. Costs and QALYs of Option B and
Option B+ were then compared using an incremental
cost-effectiveness ratio (ICER):
ICER ¼ CostOptionBþ−CostOptionB
QALYsOptionBþ−QALYsOptionB
ICER values were measured in cost per QALY gained,
and then compared to benchmarks established by the
WHO Commission on Macroeconomics for Health,
which state that “cost-effective” health interventions are
those with an ICER less than three times gross domestic
product (GDP) per capita, and “very cost-effective” inter-
ventions are those with an ICER less than GDP per
capita [24]. GDP per capita in Ghana was $3,300 (6,369
GHS) in 2012 [25].
Results
Characteristics of study population
A total of 817 medical charts were reviewed – 418 at
Suntreso Government Hospital and 399 at Kumasi
South Hospital (Table 2). The average age of first preg-
nancy was 22.78 years (SD: 4.97 years) and the average
lifetime number of children per woman was 2.34 (SD:
1.27 children). Among women whose timing of ante-
natal care access was known, 12% accessed care in their
first trimester, 40% in their second trimester, and 48%
in their third trimester.
Table 4 Baseline results of primary outcomes
Treatment
strategy
Lifetime
cost (GHS)*
Lifetime
cost (USD)*
Life-
years*
QALYs*Ϯ ICER
(USD)Ϯ
Option B 12,071 6,254 186.4 172.1
Mother 2,617 1,356 16.0 13.1
Children 9,453 4,898 178.5 159.0
Per Child 3,781 1,959 71.4 63.6
Option B+ 24,364 12,624 196.7 180.2 785
Mother 18,821 9,752 16.1 13.2
Children 5,544 2,872 178.4 167.0
Per Child 2,217 1,149 71.4 66.8
*All costs, life-years, and QALYs are discounted by 3% annual rate.
ϮQALY = Quality-Adjusted Life-Year; ICER = Incremental Cost-Effectiveness Ratio.
All QALYs are calculated using an adjustment of 0.82 utility per year when
living with HIV and an annual discount rate of 0.03.
The ICER value is calculated as follows: ICER ¼ CostOptionBþ−CostOptionBQALYsOptionBþ−QALYsOptionB :
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The time to a second pregnancy following the first preg-
nancy was taken directly from chart review data (Figure 2).
Approximately 32% of women in our sample did not have
a second pregnancy, while 4% became pregnant within one
year following their first pregnancy and 19% became preg-
nant within two years. The average time between the first
and second pregnancies was 4.56 years (SD: 3.05 years).Figure 3 Sensitivity analysis of model variables. This tornado diagram r
Each variable is listed, along with the associated incremental cost-effectivenes
cost-effectiveness of Option B+ versus Option B ($/QALY gained) as each mo
listed in descending sensitivity; those whose ICER values change most signific
GDP per capita is included on the graph, which demonstrates that Option B+
analyses. The base case ICER value is $785/QALY gained.Reduction in mother-to-child transmission
Approximately 10,800 births occur among HIV+ women
in Ghana each year [26]. Further, based on chart review,
68% of those births (7,344 births) are not the mother’s
first child. Under Option B, our model projects that the
average rate of MTCT is 10.2% during pregnancy or de-
livery. The Ghana Health Services estimates an add-
itional MTCT rate of 1% during breastfeeding [12]. If all
pregnant women in Ghana received Option B, our
model projects that 814 children would acquire HIV
from their mothers each year. Under Option B+, the
HIV transmission rate is 1% through pregnancy or deliv-
ery, and also 1% during breastfeeding. If all women in
Ghana were instead offered Option B+ and had perfect
adherence, a projected 146 infections would occur in
children each year. Offering Option B+ in lieu of Option
B could thus theoretically prevent up to 668 HIV infec-
tions among newborn babies in Ghana each year.Cost-effectiveness analysis
Our model estimates that maternal life expectancy is
16.1 years (discounted) with Option B+, compared to
16.0 years with Option B, a gain of 0.1 years on average
because of fewer treatment interruptions (Table 4). Add-
itionally, Option B+ increases average health benefits per
child from 63.6 QALYs to 66.8 QALYs, due to reducedepresents the sensitivity of different variables included in the model.
s ratio (ICER). The horizontal width of each bar represents the change in
del parameter is varied over the range given in parentheses. Variables are
antly are listed first. For reference, a vertical line indicating the Ghanaian
is a cost-effective alternative, even across a wide range of sensitivity
VanDeusen et al. BMC Infectious Diseases  (2015) 15:130 Page 8 of 10MTCT in subsequent pregnancies. Aggregating the
QALYs attributed to the mother as well as her current
child and all future children, Option B+ yields 180.2
total QALYs, a substantial gain over 172.1 QALYs ex-
pected under Option B. However, Option B+ is also
more costly, requiring lifetime total costs (discounted) of
$12,624 compared to only $6,254 with Option B. The in-
cremental cost-effectiveness is thus $785 per QALY
gained, or $618 per life-year gained (if quality-of-life
weights are ignored).Sensitivity analyses
A detailed sensitivity analysis was performed on all
model parameters, to test for robustness and identify
key parameters impacting cost-effectiveness results. Of
all variables examined, cost-effectiveness was most sensi-
tive to the cost of antiretroviral therapy for the mother
on Option B+. However, even when the annual cost of
HIV care is increased from $385 to $580, the ICER in-
creased to only $1,358 per QALY gained, still below the
Ghanaian GDP per capita of $3,300.
A tornado diagram (Figure 3) shows that the cost-
effectiveness of Option B+ was also sensitive to life ex-
pectancies, disease transmission probabilities, access to
antenatal care, and fertility rates. One-way sensitivity
analyses of several variables display each variable’s rela-
tionship to the ICER value (Figure 4). In general, as the
probability of accessing antenatal care changes from 50%
to 95%, Option B+ becomes more cost-effective because
future children are more likely to avoid HIV infection.
Conversely, as maternal life expectancy on Option B in-
creases, the cost-effectiveness of Option B+ worsensFigure 4 One-way sensitivity analyses. Each graph indicates the change
and Option B+ when a single variable’s value is changed. The “base case” scen
B+ is becoming more cost-effective as the variable’s value is increased, while a
as the variable’s value is increased. The curve of each line indicates the specificbecause the marginal gain in QALYs resulting from Op-
tion B+ diminishes.
Finally, the cost-effectiveness of Option B+ improves as
the fertility rate increases; with five children per mother,
the ICER drops to $500 per QALY gained. Of note, if we
consider only one child per mother – the assumption im-
posed by most MTCT modeling studies – we obtain an
ICER of $1,300 per QALY gained, a value 75% higher than
our initial estimate, highlighting the importance of includ-
ing future pregnancies in cost-effectiveness estimates.
Discussion
Our findings suggest that offering the Option B+ therapy
regimen to HIV+ pregnant women in Ghana improves
both maternal and child outcomes, and that the add-
itional cost of such a program is likely warranted given
its favorable cost-effectiveness. Option B+ provides con-
tinuous therapy to women during their index pregnancy
and all subsequent pregnancies. This represents a signifi-
cant improvement over Option B, whereby treatment
interruption often delays ART receipt until the second
or third trimester of later pregnancies. Our modeling
framework was novel in its ability to account for mul-
tiple pregnancies, and we find that ignoring HIV trans-
mission to future children may underestimate the
potential benefits and cost-effectiveness of Option B+.
Our study has important implications for helping pol-
icymakers allocate limited HIV resources more effect-
ively. Option B+ costs approximately $785 per QALY
gained, compared to Option B, similar to other estab-
lished HIV prevention methods in Ghana, including vol-
untary HIV counseling and blood donation screening
[4,27]. This value is in line with other HIV interventionsin the incremental cost-effectiveness ratio (ICER) between Option B
ario is indicated with a circle. A downward-sloping line indicates Option
n upward-sloping line indicates Option B+ is becoming less cost-effective
rate at which the ICER changes as the variable’s value is altered.
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countries, such as male circumcision, HIV screening and
counseling, and school-based education [28-30]. Our re-
sults are generally consistent with other model-based
studies estimating the cost-effectiveness of Option B+ in
Nigeria, Malawi, and Zimbabwe [8,9,11]. These previous
analyses demonstrated the economic merit of Option B+,
and our analysis extends these findings by incorporating
the possibility of multiple pregnancies over a woman’s
lifetime, and including primary data collection from
antenatal clinics. Based on guidelines proposed by the
WHO Commission on Macroeconomics in Health, Op-
tion B+ is considered very cost-effective compared to
Option B [24]. These results are robust to wide varia-
tions in parameter values, suggesting that Option B+ is
likely cost-effective in settings with similar resources
and epidemiologic characteristics to Ghana. A nationwide
roll-out of Option B+ would of course require investment
in health systems to ensure ART adherence and provide
early antenatal care to pregnant women. However, such
investment would likely further improve maternal and
child health outcomes for other diseases such as malaria,
tuberculosis, and childhood malnutrition.
Our modeling study has several limitations. First, be-
cause Option B+ is a newly recommended strategy, add-
itional data on its efficacy and impact on maternal life
expectancy are evolving, although we have tested varia-
tions in these assumptions in sensitivity analysis. Second,
the model does not explicitly consider horizontal HIV
transmission; however, we believe this is a reasonable as-
sumption because an HIV+ pregnant woman is likely to
have a regular partner who is also HIV+ [31]. We did
not consider variations in the duration or exclusivity of
breastfeeding practices, although variability in behavior
will inevitably exist. We estimated the expected costs and
QALYs associated with Option B and Option B+, but the
model simplifies complex clinical outcomes, such as viral
load, development of opportunistic infections, averted
costs, HIV+ women initiating ART prior to first preg-
nancy, or variability in HIV progression among children.
Conclusions
In resource-limited settings such as Ghana, systematically
comparing the potential health benefits and costs of com-
peting HIV programs can illuminate where additional in-
vestment should be prioritized. Option B+ provides
considerable health benefits to HIV+ women and their
children – especially in settings where women have mul-
tiple pregnancies – and represents good value. With na-
tionwide implementation of Option B+, we estimate that
up to 668 newborn children would be prevented from ac-
quiring HIV in Ghana every year, and preventing these in-
fections now is a key step towards reducing the burden of
HIV in the future.Additional file
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